Company: ARWR
Filing Date: 2025-03-19
Form Type: 8-K
Source: 0001628280-25-013619
Chunk: 1

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-19
Form: 8-K
Item: Item 5.07
Chunk 1
---
bo Lu                 81,171,464       1,552,680      146,030      19,860,329  
  Douglas Ingram            68,899,124      13,843,071      127,979      19,860,329  

Advisory Vote to Approve Executive Compensation

75,327,072 FOR7,389,926 AGAINST153,176 ABSTAIN19,860,329 NON VOTES

Advisory Vote on the Frequency of Future Shareholder Advisory Votes to Approve Executive Compensation

79,893,6151 YEAR211,2022 YEARS2,466,3023 YEARS299,055 ABSTAIN0 NON VOTES

Ratification of KPMG as Independent Auditors of the Company

100,977,999 FOR1,203,719 AGAINST548,785 ABSTAIN0 NON VOTES

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                  
 ────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 18, 2025

  ARROWHEAD PHARMACEUTICALS, INC.                               
  By:                                  /s/ Kenneth Myszkowski   
                                       Kenneth Myszkowski       
                                       Chief Financial Officer